• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Nature: Delta variant (B.1.617.2) sublineages do not show increased neutralization resistance

Emily

Editor, Senior Moderator
https://www.nature.com/articles/s41423-021-00772-y
Arora, P., Kempf, A., Nehlmeier, I. et al. Delta variant (B.1.617.2) sublineages do not show increased neutralization resistance. Cell Mol Immunol (2021). https://doi.org/10.1038/s41423-021-00772-y
...
Our results reveal no appreciable differences between host cell entry and neutralization sensitivity of the Delta variant and its sublineages, with the notable exception of the Delta Plus variant being resistant to both bamlanivimab and etesevimab, which are used in cocktails for COVID-19 treatment. Although T-cell responses were not analyzed in the present study and confirmation of the data using authentic virus and primary cells is pending, our results suggest that neither the Delta Plus nor the Delta-V variant is associated with an increased threat to convalescent or BNT162b2/Comirnaty vaccinated patients compared to the founder virus. Finally, it is noteworthy that heterologous ChAdOx1 nCov-19/BNT162b2 vaccination might provide particularly robust protection against these viruses [12].
 
Back
Top Bottom